{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:24:40Z","timestamp":1761060280978},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12894-017-0201-y","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T08:03:05Z","timestamp":1485849785000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer"],"prefix":"10.1186","volume":"17","author":[{"given":"Avelino","family":"Fraga","sequence":"first","affiliation":[]},{"given":"Ricardo","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Andr\u00e9","family":"Coelho","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Ramon","family":"Vizca\u00edno","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Coutinho","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Manuel","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Pr\u00edncipe","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Lobato","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,1,31]]},"reference":[{"issue":"2","key":"201_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"201_CR2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/gm166","volume":"2","author":"F Wiklund","year":"2010","unstructured":"Wiklund F. Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Genome Med. 2010;2(7):45.","journal-title":"Genome Med"},{"issue":"9","key":"201_CR3","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0210-4806(09)72891-8","volume":"33","author":"A Fraga","year":"2009","unstructured":"Fraga A, Ribeiro R, Medeiros R. Tumor hypoxia: the role of HIF. Actas Urol Esp. 2009;33(9):941\u201351.","journal-title":"Actas Urol Esp"},{"issue":"7092","key":"201_CR4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature04871","volume":"441","author":"J Pouyssegur","year":"2006","unstructured":"Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441(7092):437\u201343.","journal-title":"Nature"},{"issue":"1","key":"201_CR5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38\u201347.","journal-title":"Nat Rev Cancer"},{"key":"201_CR6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0074-7696(04)42004-X","volume":"242","author":"MC Brahimi-Horn","year":"2005","unstructured":"Brahimi-Horn MC, Pouyssegur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol. 2005;242:157\u2013213.","journal-title":"Int Rev Cytol"},{"issue":"6","key":"201_CR7","first-page":"1561","volume":"20","author":"GD Stewart","year":"2008","unstructured":"Stewart GD, Gray K, Pennington CJ, Edwards DR, Riddick AC, Ross JA, Habib FK. Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncol Rep. 2008;20(6):1561\u20137.","journal-title":"Oncol Rep"},{"issue":"1","key":"201_CR8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G","volume":"42","author":"S Gupta","year":"2000","unstructured":"Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42(1):73\u20138.","journal-title":"Prostate"},{"issue":"1","key":"201_CR9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1464-410x.2001.02231.x","volume":"88","author":"S Baltaci","year":"2001","unstructured":"Baltaci S, Orhan D, Gogus C, Turkolmez K, Tulunay O, Gogus O. Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int. 2001;88(1):100\u20133.","journal-title":"BJU Int"},{"issue":"4","key":"201_CR10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1470-2045(08)70076-7","volume":"9","author":"R Vergis","year":"2008","unstructured":"Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008;9(4):342\u201351.","journal-title":"Lancet Oncol"},{"issue":"5","key":"201_CR11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/tpj.2009.20","volume":"9","author":"AL Teixeira","year":"2009","unstructured":"Teixeira AL, Ribeiro R, Morais A, Lobo F, Fraga A, Pina F, Calais-da-Silva FM, Calais-da-Silva FE, Medeiros R. Combined analysis of EGF\u2009+\u200961G\u2009>\u2009A and TGFB1\u2009+\u2009869T\u2009>\u2009C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J. 2009;9(5):341\u20136.","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"201_CR12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039236","volume":"7","author":"RJ Ribeiro","year":"2012","unstructured":"Ribeiro RJ, Monteiro CP, Azevedo AS, Cunha VF, Ramanakumar AV, Fraga AM, Pina FM, Lopes CM, Medeiros RM, Franco EL. Performance of an adipokine pathway-based multilocus genetic risk score for prostate cancer risk prediction. PLoS ONE. 2012;7(6), e39236.","journal-title":"PLoS ONE"},{"issue":"2","key":"201_CR13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ejca.2013.09.001","volume":"50","author":"A Fraga","year":"2014","unstructured":"Fraga A, Ribeiro R, Principe P, Lobato C, Pina F, Mauricio J, Monteiro C, Sousa H, CalaisdaSilva F, Lopes C, et al. The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. Eur J Cancer. 2014;50(2):359\u201365.","journal-title":"Eur J Cancer"},{"issue":"9","key":"201_CR14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4161\/cbt.20554","volume":"13","author":"M Vainrib","year":"2012","unstructured":"Vainrib M, Golan M, Amir S, Dang DT, Dang LH, Bar-Shira A, Orr-Urtreger A, Matzkin H, Mabjeesh NJ. HIF1A C1772T polymorphism leads to HIF-1alpha mRNA overexpression in prostate cancer patients. Cancer Biol Ther. 2012;13(9):720\u20136.","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"201_CR15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/07357907.2014.883527","volume":"32","author":"Y Ye","year":"2014","unstructured":"Ye Y, Wang M, Hu S, Shi Y, Zhang X, Zhou Y, Zhao C, Wang G, Wen J, Zong H. Hypoxia-inducible factor-1alpha C1772T polymorphism and cancer risk: a meta-analysis including 18,334 subjects. Cancer Investig. 2014;32(4):126\u201335.","journal-title":"Cancer Investig"},{"issue":"2","key":"201_CR16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4161\/cbt.8.2.7086","volume":"8","author":"R Foley","year":"2009","unstructured":"Foley R, Marignol L, Thomas AZ, Cullen IM, Perry AS, Tewari P, O\u2019Grady A, Kay E, Dunne B, Loftus B, et al. The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer Biol Ther. 2009;8(2):118\u201324.","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"201_CR17","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.4161\/cbt.4.11.2091","volume":"4","author":"CH Chau","year":"2005","unstructured":"Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, Figg WD. Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther. 2005;4(11):1222\u20135.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"201_CR18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pros.20190","volume":"63","author":"XS Fu","year":"2005","unstructured":"Fu XS, Choi E, Bubley GJ, Balk SP. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate. 2005;63(3):215\u201321.","journal-title":"Prostate"},{"issue":"6","key":"201_CR19","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/aja.2012.101","volume":"14","author":"P Li","year":"2012","unstructured":"Li P, Cao Q, Shao PF, Cai HZ, Zhou H, Chen JW, Qin C, Zhang ZD, Ju XB, Yin CJ. Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population. Asian J Androl. 2012;14(6):864\u20139.","journal-title":"Asian J Androl"},{"issue":"12","key":"201_CR20","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/pros.20589","volume":"67","author":"H Li","year":"2007","unstructured":"Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J. Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate. 2007;67(12):1354\u201361.","journal-title":"Prostate"},{"key":"201_CR21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.juro.2014.10.085","volume":"193","author":"WK Ranasinghe","year":"2014","unstructured":"Ranasinghe WK, Baldwin GS, Bolton D, Shulkes A, Ischia J, Patel O. HIF1alpha expression under normoxia in prostate cancer: which pathways to target? J Urol. 2014;193:763\u201370.","journal-title":"J Urol"},{"key":"201_CR22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1756-9966-28-159","volume":"28","author":"T Zhao","year":"2009","unstructured":"Zhao T, Lv J, Zhao J, Nzekebaloudou M. Hypoxia-inducible factor-1alpha gene polymorphisms and cancer risk: a meta-analysis. J Exp Clin Cancer Res. 2009;28:159.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"201_CR23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124\u201337.","journal-title":"Eur Urol"},{"key":"201_CR24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/1471-2407-11-312","volume":"11","author":"N Pertega-Gomes","year":"2011","unstructured":"Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer. 2011;11:312.","journal-title":"BMC Cancer"},{"issue":"11","key":"201_CR25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080292","volume":"8","author":"TR Holzer","year":"2013","unstructured":"Holzer TR, Fulford AD, Nedderman DM, Umberger TS, Hozak RR, Joshi A, Melemed SA, Benjamin LE, Plowman GD, Schade AE, et al. Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung. PLoS ONE. 2013;8(11), e80292.","journal-title":"PLoS ONE"},{"issue":"2","key":"201_CR26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/pcan.2009.58","volume":"13","author":"LG Smyth","year":"2010","unstructured":"Smyth LG, O\u2019Hurley G, O\u2019Grady A, Fitzpatrick JM, Kay E, Watson RW. Carbonic anhydrase IX expression in prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(2):178\u201381.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"201_CR27","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1002\/ijc.24948","volume":"126","author":"A Albinger-Hegyi","year":"2010","unstructured":"Albinger-Hegyi A, Stoeckli SJ, Schmid S, Storz M, Iotzova G, Probst-Hensch NM, Rehrauer H, Tinguely M, Moch H, Hegyi I. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int J Cancer J International du cancer. 2010;126(11):2653\u201362.","journal-title":"Int J Cancer J International du cancer"},{"issue":"3","key":"201_CR28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399\u2013408.","journal-title":"Cell"},{"issue":"23","key":"201_CR29","first-page":"5280","volume":"58","author":"H Zhong","year":"1998","unstructured":"Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, Simons JW, Semenza GL. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res. 1998;58(23):5280\u20134.","journal-title":"Cancer Res"},{"issue":"22","key":"201_CR30","first-page":"5830","volume":"59","author":"H Zhong","year":"1999","unstructured":"Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59(22):5830\u20135.","journal-title":"Cancer Res"},{"issue":"1","key":"201_CR31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0165-4608(01)00396-X","volume":"128","author":"OR Saramaki","year":"2001","unstructured":"Saramaki OR, Savinainen KJ, Nupponen NN, Bratt O, Visakorpi T. Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer Genet Cytogenet. 2001;128(1):31\u20134.","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"201_CR32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054251","volume":"8","author":"WK Ranasinghe","year":"2013","unstructured":"Ranasinghe WK, Xiao L, Kovac S, Chang M, Michiels C, Bolton D, Shulkes A, Baldwin GS, Patel O. The role of hypoxia-inducible factor 1alpha in determining the properties of castrate-resistant prostate cancers. PLoS ONE. 2013;8(1), e54251.","journal-title":"PLoS ONE"},{"issue":"4","key":"201_CR33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/jnci\/93.4.309","volume":"93","author":"R Bos","year":"2001","unstructured":"Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, Van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001;93(4):309\u201314.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"201_CR34","first-page":"1661","volume":"7","author":"P Birner","year":"2001","unstructured":"Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res. 2001;7(6):1661\u20138.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"201_CR35","first-page":"2911","volume":"61","author":"DM Aebersold","year":"2001","unstructured":"Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;61(7):2911\u20136.","journal-title":"Cancer Res"},{"issue":"13","key":"201_CR36","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1084\/jem.20100438","volume":"207","author":"MJ Waldner","year":"2010","unstructured":"Waldner MJ, Wirtz S, Jefremow A, Warntjen M, Neufert C, Atreya R, Becker C, Weigmann B, Vieth M, Rose-John S, et al. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med. 2010;207(13):2855\u201368.","journal-title":"J Exp Med"},{"issue":"51","key":"201_CR37","doi-asserted-by":"crossref","first-page":"32521","DOI":"10.1074\/jbc.272.51.32521","volume":"272","author":"J Kroll","year":"1997","unstructured":"Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem. 1997;272(51):32521\u20137.","journal-title":"J Biol Chem"},{"issue":"46","key":"201_CR38","doi-asserted-by":"crossref","first-page":"30336","DOI":"10.1074\/jbc.273.46.30336","volume":"273","author":"HP Gerber","year":"1998","unstructured":"Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3\u2032-kinase\/Akt signal transduction pathway. Requirement for Flk-1\/KDR activation. J Biol Chem. 1998;273(46):30336\u201343.","journal-title":"J Biol Chem"},{"key":"201_CR39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1476-4598-12-147","volume":"12","author":"S Saraswati","year":"2013","unstructured":"Saraswati S, Kumar S, Alhaider AA. alpha-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT\/mTOR\/P70S6K signaling pathway. Mol Cancer. 2013;12:147.","journal-title":"Mol Cancer"},{"issue":"2","key":"201_CR40","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0022-5347(05)67414-9","volume":"164","author":"D Hahn","year":"2000","unstructured":"Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J Urol. 2000;164(2):506\u201310.","journal-title":"J Urol"},{"issue":"3","key":"201_CR41","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0090-4295(99)00156-9","volume":"54","author":"FA Ferrer","year":"1999","unstructured":"Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 1999;54(3):567\u201372.","journal-title":"Urology"},{"issue":"8","key":"201_CR42","first-page":"857","volume":"21","author":"J Pallares","year":"2006","unstructured":"Pallares J, Rojo F, Iriarte J, Morote J, Armadans LI, De Torres I. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol. 2006;21(8):857\u201365.","journal-title":"Histol Histopathol"},{"issue":"4","key":"201_CR43","first-page":"324","volume":"13","author":"AS Bai","year":"2007","unstructured":"Bai AS, Zeng H, Li X, Wei Q, Li H, Yang YR. Expression of kinase insert domain-containing receptor in prostate adenocarcinoma. Zhonghua nan ke xue\u2009=\u2009National journal of andrology. 2007;13(4):324\u20136.","journal-title":"Zhonghua nan ke xue\u2009=\u2009National journal of andrology"},{"issue":"3","key":"201_CR44","first-page":"770","volume":"19","author":"J Song","year":"2014","unstructured":"Song J, Song Y, Guo W, Jia J, Jin Y, Bai A. Regulatory roles of KDR antisense oligonucleotide on the proliferation of human prostate cancer cell line PC-3. J BUON. 2014;19(3):770\u20134.","journal-title":"J BUON"},{"issue":"1","key":"201_CR45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/PPO.0b013e31827e0b86","volume":"19","author":"MT Schweizer","year":"2013","unstructured":"Schweizer MT, Carducci MA. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer. Cancer J. 2013;19(1):99\u2013106.","journal-title":"Cancer J"},{"issue":"10","key":"201_CR46","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.clon.2007.06.014","volume":"19","author":"BT Sherwood","year":"2007","unstructured":"Sherwood BT, Colquhoun AJ, Richardson D, Bowman KJ, O\u2019Byrne KJ, Kockelbergh RC, Symonds RP, Mellon JK, Jones GD. Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer. Clin Oncol. 2007;19(10):777\u201383.","journal-title":"Clin Oncol"},{"issue":"3","key":"201_CR47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1200\/JCO.2003.11.132","volume":"21","author":"DE Swinson","year":"2003","unstructured":"Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O\u2019Byrne KJ. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003;21(3):473\u201382.","journal-title":"J Clin Oncol"},{"issue":"2","key":"201_CR48","first-page":"802","volume":"9","author":"MH Bui","year":"2003","unstructured":"Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9(2):802\u201311.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"201_CR49","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.juro.2007.03.112","volume":"178","author":"JJ Ord","year":"2007","unstructured":"Ord JJ, Agrawal S, Thamboo TP, Roberts I, Campo L, Turley H, Han C, Fawcett DW, Kulkarni RP, Cranston D, et al. An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J Urol. 2007;178(2):677\u201382.","journal-title":"J Urol"},{"issue":"24","key":"201_CR50","first-page":"7075","volume":"60","author":"CC Wykoff","year":"2000","unstructured":"Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60(24):7075\u201383.","journal-title":"Cancer Res"},{"issue":"1","key":"201_CR51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ijc.23934","volume":"124","author":"GD Stewart","year":"2009","unstructured":"Stewart GD, Nanda J, Brown DJ, Riddick AC, Ross JA, Habib FK. NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer J International du cancer. 2009;124(1):223\u201332.","journal-title":"Int J Cancer J International du cancer"},{"key":"201_CR52","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/1471-2407-14-352","volume":"14","author":"N Pertega-Gomes","year":"2014","unstructured":"Pertega-Gomes N, Vizcaino JR, Attig J, Jurmeister S, Lopes C, Baltazar F. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer. 2014;14:352.","journal-title":"BMC Cancer"},{"issue":"7","key":"201_CR53","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/pros.22620","volume":"73","author":"N Pertega-Gomes","year":"2013","unstructured":"Pertega-Gomes N, Vizcaino JR, Gouveia C, Jeronimo C, Henrique RM, Lopes C, Baltazar F. Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate. 2013;73(7):763\u20139.","journal-title":"Prostate"},{"issue":"3","key":"201_CR54","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.bbrc.2009.06.064","volume":"386","author":"Y Li","year":"2009","unstructured":"Li Y, Wang H, Oosterwijk E, Selman Y, Mira JC, Medrano T, Shiverick KT, Frost SC. Antibody-specific detection of CAIX in breast and prostate cancers. Biochem Biophys Res Commun. 2009;386(3):488\u201392.","journal-title":"Biochem Biophys Res Commun"},{"key":"201_CR55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1748-717X-7-66","volume":"7","author":"DC Weber","year":"2012","unstructured":"Weber DC, Tille JC, Combescure C, Egger JF, Laouiti M, Hammad K, Granger P, Rubbia-Brandt L, Miralbell R. The prognostic value of expression of HIF1alpha, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Radiat Oncol. 2012;7:66.","journal-title":"Radiat Oncol"},{"issue":"37","key":"201_CR56","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1038\/sj.onc.1206703","volume":"22","author":"NC Denko","year":"2003","unstructured":"Denko NC, Fontana LA, Hudson KM, Sutphin PD, Raychaudhuri S, Altman R, Giaccia AJ. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene. 2003;22(37):5907\u201314.","journal-title":"Oncogene"},{"issue":"3","key":"201_CR57","volume":"3","author":"JT Chi","year":"2006","unstructured":"Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006;3(3), e47.","journal-title":"PLoS Med"},{"issue":"7088","key":"201_CR58","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nature04695","volume":"440","author":"JT Erler","year":"2006","unstructured":"Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440(7088):1222\u20136.","journal-title":"Nature"},{"issue":"15","key":"201_CR59","first-page":"4478","volume":"62","author":"DA Kirschmann","year":"2002","unstructured":"Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K, Hendrix MJ. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res. 2002;62(15):4478\u201383.","journal-title":"Cancer Res"},{"issue":"2","key":"201_CR60","first-page":"497","volume":"150","author":"S Peyrol","year":"1997","unstructured":"Peyrol S, Raccurt M, Gerard F, Gleyzal C, Grimaud JA, Sommer P. Lysyl oxidase gene expression in the stromal reaction to in situ and invasive ductal breast carcinoma. Am J Pathol. 1997;150(2):497\u2013507.","journal-title":"Am J Pathol"},{"issue":"6","key":"201_CR61","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0714.1999.tb02033.x","volume":"28","author":"C Trivedy","year":"1999","unstructured":"Trivedy C, Warnakulasuriya KA, Hazarey VK, Tavassoli M, Sommer P, Johnson NW. The upregulation of lysyl oxidase in oral submucous fibrosis and squamous cell carcinoma. J Oral Pathol Med. 1999;28(6):246\u201351.","journal-title":"J Oral Pathol Med"},{"key":"201_CR62","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-9966-31-32","volume":"31","author":"R Ribeiro","year":"2012","unstructured":"Ribeiro R, Monteiro C, Cunha V, Oliveira MJ, Freitas M, Fraga A, Principe P, Lobato C, Lobo F, Morais A, et al. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. J Exp Clin Cancer Res. 2012;31:32.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"201_CR63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/pros.20433","volume":"67","author":"A Orr-Urtreger","year":"2007","unstructured":"Orr-Urtreger A, Bar-Shira A, Matzkin H, Mabjeesh NJ. The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. Prostate. 2007;67(1):8\u201313.","journal-title":"Prostate"},{"issue":"11","key":"201_CR64","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/carcin\/bgg132","volume":"24","author":"K Tanimoto","year":"2003","unstructured":"Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis. 2003;24(11):1779\u201383.","journal-title":"Carcinogenesis"},{"issue":"11","key":"201_CR65","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/mc.20209","volume":"45","author":"K Fransen","year":"2006","unstructured":"Fransen K, Fenech M, Fredrikson M, Dabrosin C, Soderkvist P. Association between ulcerative growth and hypoxia inducible factor-1alpha polymorphisms in colorectal cancer patients. Mol Carcinog. 2006;45(11):833\u201340.","journal-title":"Mol Carcinog"},{"issue":"11","key":"201_CR66","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1073\/pnas.94.11.5667","volume":"94","author":"PJ Kallio","year":"1997","unstructured":"Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci U S A. 1997;94(11):5667\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"201_CR67","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1159\/000356593","volume":"32","author":"F Wu","year":"2013","unstructured":"Wu F, Zhang J, Liu Y, Zheng Y, Hu N. HIF1alpha genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC. Cell Physiol Biochem. 2013;32(6):1566\u201376.","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"201_CR68","first-page":"1181","volume":"20","author":"HO Kim","year":"2008","unstructured":"Kim HO, Jo YH, Lee J, Lee SS, Yoon KS. The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer. Oncol Rep. 2008;20(5):1181\u20137.","journal-title":"Oncol Rep"},{"issue":"8","key":"201_CR69","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jacc.2007.04.074","volume":"50","author":"Y Wang","year":"2007","unstructured":"Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, Qin Q, Zhao B, Yang Y, Hui R. Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol. 2007;50(8):760\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"201_CR70","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1002\/mc.21980","volume":"52","author":"MJ Jang","year":"2013","unstructured":"Jang MJ, Jeon YJ, Kim JW, Cho YK, Lee SK, Hwang SG, Oh D, Kim NK. Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans. Mol Carcinog. 2013;52 Suppl 1:E60\u201369.","journal-title":"Mol Carcinog"},{"issue":"3","key":"201_CR71","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1349-7006.2011.02194.x","volume":"103","author":"G Dong","year":"2012","unstructured":"Dong G, Guo X, Fu X, Wan S, Zhou F, Myers RE, Bao G, Burkart A, Yang H, Xing J. Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer. Cancer Sci. 2012;103(3):561\u20138.","journal-title":"Cancer Sci"},{"issue":"2","key":"201_CR72","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.juro.2009.03.077","volume":"182","author":"M De Martino","year":"2009","unstructured":"De Martino M, Klatte T, Seligson DB, LaRochelle J, Shuch B, Caliliw R, Li Z, Kabbinavar FF, Pantuck AJ, Belldegrun AS. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol. 2009;182(2):728\u201334.","journal-title":"J Urol"},{"issue":"12","key":"201_CR73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051051","volume":"7","author":"MH Chien","year":"2012","unstructured":"Chien MH, Yang JS, Chu YH, Lin CH, Wei LH, Yang SF, Lin CW. Impacts of CA9 gene polymorphisms and environmental factors on oral-cancer susceptibility and clinicopathologic characteristics in Taiwan. PLoS ONE. 2012;7(12), e51051.","journal-title":"PLoS ONE"},{"issue":"12","key":"201_CR74","doi-asserted-by":"crossref","first-page":"8666","DOI":"10.1016\/S0021-9258(18)42494-5","volume":"267","author":"PC Trackman","year":"1992","unstructured":"Trackman PC, Bedell-Hogan D, Tang J, Kagan HM. Post-translational glycosylation and proteolytic processing of a lysyl oxidase precursor. J Biol Chem. 1992;267(12):8666\u201371.","journal-title":"J Biol Chem"},{"issue":"25","key":"201_CR75","doi-asserted-by":"crossref","first-page":"22537","DOI":"10.1074\/jbc.M102352200","volume":"276","author":"MI Uzel","year":"2001","unstructured":"Uzel MI, Scott IC, Babakhanlou-Chase H, Palamakumbura AH, Pappano WN, Hong HH, Greenspan DS, Trackman PC. Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. J Biol Chem. 2001;276(25):22537\u201343.","journal-title":"J Biol Chem"},{"issue":"3","key":"201_CR76","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/0008-5472.CAN-06-3867","volume":"67","author":"C Min","year":"2007","unstructured":"Min C, Kirsch KH, Zhao Y, Jeay S, Palamakumbura AH, Trackman PC, Sonenshein GE. The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2\/neu-driven breast cancer. Cancer Res. 2007;67(3):1105\u201312.","journal-title":"Cancer Res"},{"issue":"7","key":"201_CR77","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1128\/MCB.23.7.2251-2263.2003","volume":"23","author":"S Jeay","year":"2003","unstructured":"Jeay S, Pianetti S, Kagan HM, Sonenshein GE. Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. Mol Cell Biol. 2003;23(7):2251\u201363.","journal-title":"Mol Cell Biol"},{"issue":"16","key":"201_CR78","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1158\/0008-5472.CAN-08-4818","volume":"69","author":"C Min","year":"2009","unstructured":"Min C, Yu Z, Kirsch KH, Zhao Y, Vora SR, Trackman PC, Spicer DB, Rosenberg L, Palmer JR, Sonenshein GE. A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer Res. 2009;69(16):6685\u201393.","journal-title":"Cancer Res"},{"issue":"24","key":"201_CR79","doi-asserted-by":"crossref","first-page":"11429","DOI":"10.1158\/0008-5472.CAN-05-1274","volume":"65","author":"SL Payne","year":"2005","unstructured":"Payne SL, Fogelgren B, Hess AR, Seftor EA, Wiley EL, Fong SF, Csiszar K, Hendrix MJ, Kirschmann DA. Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res. 2005;65(24):11429\u201336.","journal-title":"Cancer Res"},{"issue":"6","key":"201_CR80","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/jcb.21371","volume":"101","author":"SL Payne","year":"2007","unstructured":"Payne SL, Hendrix MJ, Kirschmann DA. Paradoxical roles for lysyl oxidases in cancer--a prospect. J Cell Biochem. 2007;101(6):1338\u201354.","journal-title":"J Cell Biochem"},{"issue":"1","key":"201_CR81","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccr.2008.11.012","volume":"15","author":"JT Erler","year":"2009","unstructured":"Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT, Giaccia AJ. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009;15(1):35\u201344.","journal-title":"Cancer Cell"},{"issue":"1","key":"201_CR82","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10585-008-9209-8","volume":"26","author":"JT Erler","year":"2009","unstructured":"Erler JT, Weaver VM. Three-dimensional context regulation of metastasis. Clin Exp Metastasis. 2009;26(1):35\u201349.","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"201_CR83","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2133.1994.tb08518.x","volume":"131","author":"H Kobayashi","year":"1994","unstructured":"Kobayashi H, Ishii M, Chanoki M, Yashiro N, Fushida H, Fukai K, Kono T, Hamada T, Wakasaki H, Ooshima A. Immunohistochemical localization of lysyl oxidase in normal human skin. Br J Dermatol. 1994;131(3):325\u201330.","journal-title":"Br J Dermatol"},{"issue":"3","key":"201_CR84","first-page":"377","volume":"63","author":"H Wakasaki","year":"1990","unstructured":"Wakasaki H, Ooshima A. Immunohistochemical localization of lysyl oxidase with monoclonal antibodies. Lab Investig. 1990;63(3):377\u201384.","journal-title":"Lab Investig"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-017-0201-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T04:47:40Z","timestamp":1719031660000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-017-0201-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,31]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["201"],"URL":"https:\/\/doi.org\/10.1186\/s12894-017-0201-y","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,31]]},"article-number":"12"}}